ArticleEndocrine connections2026
Harmonization of IGF1 immunoassays towards a higher-order LC-MS/MS reference anchor.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Despite the universal calibration of commercial IGF1 immunoassays to WHO IS 02/254, substantial inter-assay variability persists, leading to inconsistent patient classification. Harmonization towards a higher-order analytical anchor may reduce such variability. Methods: Four matrix-matched, multi-level serum reference materials (RMs) were prepared from donor serum and value-assigned using an LC-MS/MS method calibrated to WHO IS 02/254. Commutability was assessed according to IFCC recommendations across four immunoassays (Cobas, iSYS, Immulite, Liaison). Deming regression-based recalibration equations derived from commutable RMs were applied to patient samples and healthy donor samples. The primary quantitative endpoint was reduction in standard error of estimate (SEE) relative to the LC-MS/MS method. Age- and sex-specific LC-MS/MS-anchored reference intervals were constructed as a downstream application. Results: Prior to recalibration, immunoassays showed positive bias relative to LC-MS/MS of up to 60%. All four RMs were commutable for Liaison and iSYS, whereas the lowest concentration RM was classified as non-commutable for Cobas and Immulite. Recalibration towards the LC-MS/MS anchor resulted in marked alignment towards the identity line and reduced pooled SEE from 7.82 to 4.89 nmol/L (-37.4%) in patient samples and from 7.34 to 2.09 nmol/L (-71.5%) in healthy samples. Although harmonization effects were assay-dependent at the individual platform level, overall cross-platform dispersion was substantially attenuated. Conclusions: Matrix-matched, commutable serum RMs value-assigned by a higher-order LC-MS/MS procedure enable substantial reduction of inter-assay bias and variability among IGF1 immunoassays. Harmonization towards a higher-order analytical anchor is achievable in routine practice and provides a robust foundation for consistent cross-platform interpretation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.